Corcept Therapeutics Inc. (CORT) — Analysis Summary
Corcept Therapeutics Inc. (CORT) has a market cap of $9.22B with year-over-year revenue growth of +12.8%. Net margin stands at 13.1%. The stock trades at a P/E ratio of 194.8.
Key Takeaways
- Revenue changed +12.8% year-over-year
- Net margin of 13.1%
- P/E ratio of 194.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, CORT posted revenue growth of +12.8% and trades at a P/E of 194.8.
Corcept Therapeutics Inc. (CORT)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Net income fell 52.5% vs the prior period.
Gross margin at 98.3% — verify: very few businesses sustain >90% gross margin outside pure software/IP
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
730
Headquarters
REDWOOD CITY, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.